Press Releases Solasia Pharma K.K.

Equities

4597

JP3436500007

Delayed Japan Exchange Other stock markets 01:55:29 2024-05-01 am EDT			5-day change	1st Jan Change
26 ^JPY	0.00%		+8.00%	-40.00%

Mar. 04	Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	CI
Feb. 16	Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	Mar. 19	AQ
Solasia Announces Launch of Darvias® in Japan	22-08-22	BU
Solasia Pharma K K : Business Overview of Pipeline Products (first six months of the Fiscal Year Ending December 31, 2022)	22-08-15	PU
Solasia Pharma K K : Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (under IFRS)	22-08-15	PU
Solasia Pharma K K : Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)	22-08-03	PU
Solasia acquires episil oral liquid business from Camurus	22-07-08	AQ
Solasia Pharma K K : Announces Capital and Business Alliance with Nippon Kayaku Co., Ltd.	22-06-28	PU
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan	22-06-19	BU
DARVIAS Injection 135mg (generic name: DARINAPARSIN /development code: SP-02) approved in Japan	22-06-19	PU
Solasia Pharma K K : Partner, Isofol announced start of study data analysis of SP-05 (arfolitixorin) phase III AGENT study	22-04-24	PU
Solasia Pharma K K : Announcement of the matters to be resolved at the Ordinary General Meeting of Shareholders (March 24, 2022.)	22-02-21	PU
Solasia Pharma K K : Announces Finance via Issuance of Unsecured Straight Bond and Warrant	22-02-14	PU
Solasia Pharma K K : Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer	21-11-24	PU
Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2021)	21-11-10	PU
Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2021 (under IFRS)	21-11-10	PU
Solasia Announces Revision to Full-Year Earnings Forecast	21-11-10	PU
Solasia Pharma K K : Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2021 (under IFRS)	21-08-11	PU
Solasia Pharma K K : Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2021)	21-08-11	PU
Solasia Pharma K K : Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan	21-06-30	BU
Solasia Pharma K K : Announces Exercise Price Revisions Associated with Series 12 Warrants	21-06-30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Solasia Pharma K.K.

Equities

4597

JP3436500007

Press Releases

Filters